Heterozygous p53 knockout mice were investigated as a potential model for vascular tumor carcinogenesis. Groups of 20 male mice were exposed by gavage for 6 months to the vascular carcinogen urethane at 1, 10, or 100 mg/kg body weight/day. Wild-type and heterozygous p53 knockout control groups were exposed by gavage to the vehide alone. Another group of 20 male mice received etlimonene by gavage (dtlimonene is noncarcinogenic in mice). The high dose of urethane caused early mortality in the majority of mice associated with histopathologic evidence oftoxicity and tumors, including a high incidence of benign and malignant vascular tumors, in all animals. At the intermediate dose, toxicity was less marked and 3 of 20 mice had tumors; mice that received the low dose did not have signs of toxicity or neoplasia. The two control groups had no tumors and the ilimonene group had one tumor of the prostate, which was considered spontaneous. We conclude that the p53 knockout mouse is a useful tool for investigating vascular tumorogenesis.
knockout control groups were exposed by gavage to the vehide alone. Another group of 20 male mice received etlimonene by gavage (dtlimonene is noncarcinogenic in mice). The high dose of urethane caused early mortality in the majority of mice associated with histopathologic evidence oftoxicity and tumors, including a high incidence of benign and malignant vascular tumors, in all animals. At The p53 knockout mouse is the subject of great interest for its potential as a tool to study chemical carcinogenesis. The heterozygote could be used in carcinogenicity testing strategies that would potentially reduce the number of full-scale lifetime studies in conventional mouse models (1, 2) . Because heterozygous p53 knockout mice should be more sensitive to carcinogens than normal mice, such rodent bioassays would use fewer animals and take less time. Furthermore, because heterozygous p53 knockout mice have a low incidence of tumors until 9-12 months of age, it should be easier to identify the treatment-related effects of chemicals in a mouse strain with a low background of spontaneous cancers (3, 4) . After 12 months of age, the rate of tumor development accelerates and by 18 months of age, 50% of the heterozygous mice have succumbed to tumors, mainly osteosarcomas, malignant lymphomas, and hemangiosarcomas. Therefore, 6 months is a suitable test duration; the expected yield of spontaneous tumors should be low.
Mice, as with other experimental species, have a strain-dependent profile of tumor types. Hepatocellular tumors are common in many strains of mice and are the subject of much discussion with respect to their relevance in carcinogen evaluation (5, 6) . Lung tumors and lymphoreticular tumors are also relatively common. Although vascular tumors are also found, they usually occur at a relatively low incidence (7, 8 To explore the potential of the p53 knockout mouse for studying vascular tumors we selected the genotoxic compound urethane, which produces these tumors in lifetime studies in mice. Urethane, which is genotoxic via the formation of a reactive electrophilic metabolite, vinyl carbamate epoxide (10) , has well-documented carcinogenic activity in rodent models; studies date back more than 20 years (11) . Urethane was previously used as an anesthetic, but is also a natural compound found in low concentrations in many fermentation products (12) .
One of the assumptions with the knockout model is that a mutation at the intact p53 allele is necessary for development of the carcinogenic process. In principle, nongenotoxic compounds that induce tumors by other mechanisms should be negative in this system. Therefore, d-limonene, which is neither genotoxic nor carcinogenic in mice but is carcinogenic in the male rat by a nongenotoxic mechanism (13) (14) (15) , was included as a negative control substance.
The criteria established for assessing the usefulness of this model were (16) . Four groups of 20 male heterozygous p53 knockout mice (p53+1-), 8 weeks of age at the start of treatment, were dosed daily by gavage [5 mL/kg body weight (bw)] with urethane at 1, 10, and 100 mg/kg/day, respectively, or with d-limonene at 250 mg/kg/day for at least 180 days. These dose levels were based on published mouse bioassay data (17) (18) (19) other tissues (liver, kidney, lung, spleen, heart, ng/kg/day. cDose level 10 mg/kg/day. dDose level 100 mg/kg/day. 0ose level 250 adrenal gland, sternum, subcutis, aorta, and ble for the eye in the 100 mg/kg/day group. 9All types of tumors.
spinal cord). Six (30%) of the 100 mg/kg/day mice had generalized atrophy/involution of the thymus as did one mouse at 10 mg/kg/day. Cortical lymphocytolysis/apoptosis was noted in 5 (25%) of the mice that received 100 mg/kg/day. No changes were noted at 1 mg/kg/day.
Lung. We found bronchioloalveolar adenomas ( Figure 5 ) in 5 mice (25%) treated at 100 mglkg/day. Interstitial mononuclear cell infiltrate of the pulmonary parenchyma was noted in 15 of 20 (75%) of the mice at the same dose level. No significant changes were found at 10 and 1 mg/kg/day. Subcutis. A large subcutaneous sarcoma was present in a single p53 knockout mouse treated at 10 mg/kg/day and in one treated at 100 mg/kg/day.
Testis. Twenty-five percent of the mice from the 10 and 100 mg/kg/day group had diffuse atrophy of the seminiferous tubules.
Eye. Twelve of 13 (92%) of the mice treated with urethane at 100 mg/kg/day had bilateral retinal atrophy consisting of the complete loss of the bacillary, outer nuclear, and outer plexiform layers of the eye. 
Discussion
The p53 knockout mouse model is used in fundamental studies of the mechanisms of carcinogenesis (3, (23) (24) (25) (26) . To better understand the role of the p53 gene in this process, the model is also under validation for its usefulness as a more sensitive rodent model for identifying potential carcinogens (1, 3) .
Our purpose was to test whether heterozygous p53-deficient mice are a good model to detect vascular tumors caused by genotoxic carcinogens using urethane as a positive control. Urethane is a well-known carcinogen that forms a reactive electrophilic metabolite (10 Volume 108, Number 1, January 2000 * Environmental Health Perspectivesknockout mice, were also present in the 100 mg/kg/day urethane group. We also obtained a dose-related effect with urethane treatment; no tumor was detected at 1 mg/kg/day and there was only a low incidence of tumors at 10 mglkg/day.
Inai et al. (19) used a range of urethane doses that can be compared to ours for the purposes of making conclusions about the sensitivity of the model. In their study, dose levels equivalent to 1, 10, and 100 mg/kg bw/day were administered in drinking water to B6C3F1 mice for 70 weeks. Their study also found early death in the highest dose (600 ppm; approximately 100 mg/kg/day). In addition, the authors considered the early mortality to be attributable to the rupture of the vascular tumors, which occurred in approximately 80% of the high dose mice. Inai et al. (19) showed a few vascular tumors at 10 mg/kg/day; at lower doses the incidence was comparable to background. Their study showed a lower threshold for detecting lung tumors (significant increases were seen at 10 mg/kg/day), whereas we had none at this dose. However, Inai et al. (19) had an 18.4% incidence of this tumor in controls. Considering the differences in experimental design, the coherence of the results between these two studies appears remarkably good.
No tumors were seen in untreated heterozygous p53 knockout mice or in the wild-type mice. d-Limonene, which is not genotoxic or carcinogenic in mice, did not induce any treatment-related tumors in heterozygous p53 knockout mice. The single adenoma of the prostate was considered incidental. d-Limonene caused signs of chronic irritation of the nonglandular stomach that were associated with hyperplasia but not neoplasia. Field and Roe (28) reported similar lesions, associated with the irritant effect of the compound.
Thus, the p53 model proved efficient for the induction of vascular tumors. It was possible to induce a high incidence of hemangioma and/or hemangiosarcoma in the heterozygous p53 knockout mice treated with urethane in a short period of time as compared to a classical 2-year bioassay for carcinogenicity studies. The appearance of the tumors was dose related with neither neoplastic nor nonneoplastic proliferative findings at the low dose. There were no vascular tumors in the untreated animals or in animals treated with d-limonene. Therefore, we consider that our three criteria for the usefulness of the model were met, namely: zero incidence of vascular tumors in untreated p53 knockout mice, untreated wild-type mice, and in d-limonene-treated p53 knockout mice (at 6 months); a high incidence of vascular tumors in p53 knockout mice receiving toxic doses of urethane; and a doserelated decrease in vascular tumors in p53 knockout mice with lower doses of urethane.
In conclusion, the heterozygous p53 knockout mouse seems to be a good model for identifying vascular tumors. The essentially nonexistent level of vascular tumors in control p53 knockout mice might make this system particularly suitable for studying low potency compounds suspected of being vascular carcinogens.
